NCT02581007 · FLOW
Participant flow
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- groups
- description
- Fludarabine, Melphalan \& Post-transplant cyclophosphamide Fludarabine: fludarabine (30mg/m2) given every day starting on Day -6 through Day -2; Melphalan Cyclophosphamide: cyclophosphamide (50mg/kg) given every day starting on Day 3 through Day 4. peripheral blood stem cell transplant
- id
- FG000
- title
- Reduced-Intensity Mismatched Transplant
- periods
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 25
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 25
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 0
- type
- NOT COMPLETED
- title
- Overall Study
Complete source fields
- groups
- description
- Fludarabine, Melphalan \& Post-transplant cyclophosphamide Fludarabine: fludarabine (30mg/m2) given every day starting on Day -6 through Day -2; Melphalan Cyclophosphamide: cyclophosphamide (50mg/kg) given every day starting on Day 3 through Day 4. peripheral blood stem cell transplant
- id
- FG000
- title
- Reduced-Intensity Mismatched Transplant
- periods
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 25
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 25
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 0
- type
- NOT COMPLETED
- title
- Overall Study
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle